Zoey Becker

6 days ago | fiercebiotech.com | Darren Incorvaia |Zoey Becker

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren Incorvaia or Zoey Becker and it will be featured here at the end of each week.

1 week ago | fiercebiotech.com | Zoey Becker

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed. Through the deal, Merck gains non-exclusive global rights to Cyprumed’s oral peptide delivery platform for an undisclosed number of targets, plus the option to exclusively license the tech for other individual targets.

1 week ago | fiercepharma.com | Zoey Becker

Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) turned out to be a conclusive failure, leaving the company with one fewer avenue to boost the drug's long-term growth trajectory. The Camzyos maker initiated the “largest and longest-duration study” to date in patients with nHCM to see if its drug could offer the same benefits as it does in obstructive HCM (oHCM).

1 week ago | fiercepharma.com | Zoey Becker

Ever since President Donald Trump nominated Robert F. Kennedy Jr. to the HHS secretary position, Kennedy has taken steps to publicly distance himself from unpopular and conspiratorial views he's shared in the past. But in a Friday speech to FDA employees, the HHS secretary laid bare his belief that the agency hasn't always acted in the best interest of Americans—going many steps further in his own colorful language.

1 week ago | fiercepharma.com | Zoey Becker

Nearly a year after winning an accelerated approval for its DLL3-targeting small cell lung cancer (SCLC) therapy Imdelltra, Amgen is further proving the drug's worth with overall survival data from an interim analysis of a phase 3 study.